<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662019000300460</article-id>
<article-id pub-id-type="doi">10.24245/mim.v35i3.2381</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Respuesta al tratamiento inmunomodulador como criterio diagnóstico de cirrosis por hepatitis autoinmunitaria en una adulta colombiana]]></article-title>
<article-title xml:lang="en"><![CDATA[Response to immunomodulator treatment as diagnostic criterion of cirrhosis due to autoimmune hepatitis in a Colombian adult]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cáceres-Delgado]]></surname>
<given-names><![CDATA[Laura Camila]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortiz-Henao]]></surname>
<given-names><![CDATA[Jesús Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Delgado-Galeano]]></surname>
<given-names><![CDATA[Mayut]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Ayala]]></surname>
<given-names><![CDATA[Jaime Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Autónoma de Bucaramanga Escuela de Medicina Facultad de Salud]]></institution>
<addr-line><![CDATA[ Bucaramanga]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Industrial de Santander Facultad de Salud ]]></institution>
<addr-line><![CDATA[ Bucaramanga]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>3</numero>
<fpage>460</fpage>
<lpage>470</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662019000300460&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662019000300460&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662019000300460&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La hepatitis autoinmunitaria es una enfermedad inflamatoria progresiva que daña directamente los hepatocitos, a largo plazo y sin tratamiento oportuno lleva a cirrosis. En todo el mundo se estiman 11.6-35.9 casos/100,000 habitantes, por tanto, en la práctica médica es poco considerada entre los diagnósticos de hepatitis crónica; entre otras causas, debido a que los criterios diagnósticos simplificados para esta enfermedad son complejos, pues se centran en medios diagnósticos costosos y en países de bajos y medianos ingresos, se dificulta el acceso, la oportunidad del diagnóstico y el tratamiento, además, es importante considerar la sensibilidad de éstos. Se comunica el caso clínico de una paciente adulta con características clínicas de cirrosis por hepatitis autoinmunitaria, en quien la utilización de los métodos diagnósticos recomendados no favoreció el diagnóstico de enfermedad autoinmunitaria. El caso comunicado es atípico, destaca la mejoría clínica con el tratamiento inmunomodulador como criterio diagnóstico único de los criterios clásicos de 1999 para establecer el diagnóstico de hepatitis autoinmunitaria por la elevada sensibilidad de la respuesta al tratamiento evidenciada a las 48 horas. Es importante considerar el inicio del tratamiento inmunomodulador contra la hepatitis autoinmunitaria una vez descartadas las principales causas de hepatopatía crónica, a pesar de no cumplir los criterios diagnósticos, con lo que se frenó el avance de la enfermedad y el desenlace fatal en el paciente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Autoimmune hepatitis is a progressive inflammatory disease that directly attacks the hepatocytes, in the long term and without timely treatment leads to cirrhosis. Worldwide, it is estimated between 11.6-35.9 cases/100,000 inhabitants, therefore, in medical practice it is low considered in the diagnosis of chronic hepatitis; because the simplified diagnostic criteria for this disease are complex, insofar as they focus on costly diagnostic means, and in lowand middle-income countries, it makes difficult the access, the opportunity for diagnosis and treatment. In addition, it is important to consider the sensitivity of these diagnostic means. This paper reports the clinical case of an adult woman with clinical features of cirrhosis due to autoimmune hepatitis, in which the use of recommended diagnostic methods did not directly favor the diagnosis of autoimmune disease. This clinical case is atypical, highlighting the clinical improvement with immunosuppressive treatment, considered a single diagnostic criterion of the classical criteria of 1999 to determine the diagnosis of autoimmune hepatitis, due to the high sensitivity of the response to the treatment evidenced at 48 hours. It is important to consider the initiation of immunosuppressive treatment of hepatitis autoinmunitaria, once the main causes of chronic liver disease have been ruled out, despite not meeting the diagnostic criteria, thus slowing the progression of the disease and a fatal outcome in the patient.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hepatitis autoinmunitaria]]></kwd>
<kwd lng="es"><![CDATA[cirrosis hepática]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos antinucleares]]></kwd>
<kwd lng="en"><![CDATA[Autoimmune hepatitis]]></kwd>
<kwd lng="en"><![CDATA[Liver cirrhosis]]></kwd>
<kwd lng="en"><![CDATA[Antibodies]]></kwd>
<kwd lng="en"><![CDATA[Antinuclear]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liberal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[CR.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cirrhosis and autoimmune liver disease: Current understanding]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Czaja]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Carpenter]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2004</year>
<volume>39</volume>
<page-range>1631-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giraldo Montoya]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Barraza Amador]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Villa Velásquez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[García Castro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización epidemiológica de pacientes con cirrosis en una consulta de gastroenterología en Pereira, Colombia, 2009-2012]]></article-title>
<source><![CDATA[Rev Méd Risaralda]]></source>
<year>2014</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>86-94</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdivia Correa]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chablé Montero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez Sánchez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of chronic autoimmune liver disease A histopathological study in third-level hospital in Mexico City]]></article-title>
<source><![CDATA[Rev Invest Med Sur Mex]]></source>
<year>2016</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ginèsa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrerab]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guevaraa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morillasc]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz del Árbold]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Solàe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Documento de consenso sobre el tratamiento de la ascitis, la hiponatremia dilucional y el síndrome hepatorrenal en la cirrosis hepática]]></article-title>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2004</year>
<numero>9</numero>
<issue>9</issue>
<page-range>535-44</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-Analysis Diagnostic Accuracy of Antinuclear Antibodies, Smooth Muscle Antibodies and Antibodies to a Soluble Liver Antigen/Liver Pancreas in Autoimmune Hepatitis]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2014</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hennes]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Zeniya]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Czaja]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pares]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dalekos]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Krawitt]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Simplified diagnostic criteria for autoimmune hepatitis]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2008</year>
<volume>48</volume>
<page-range>169-76</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Czaja]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Performance parameters of the diagnostic scoring systems for autoimmune hepatitis]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2008</year>
<volume>48</volume>
<page-range>1540-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Correa Gaviria]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo Gutiérrez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Osorio Sandoval]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza Herrera]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reporte de un caso de falla hepática aguda por hepatitis autoinmune en una paciente en tratamiento con interferón pegilado para infección crónica por el virus de la hepatitis C]]></article-title>
<source><![CDATA[Revista Colombiana de Gastroenterología, Endoscopia digestiva, Coloproctología y Hepatología]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trivedi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hirschfield]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of autoimmune liver disease current and future therapeutic options]]></article-title>
<source><![CDATA[Ther Adv Chronic Dis]]></source>
<year>2013</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>119-41</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<source><![CDATA[Auto-anticuerpos en las enfermedades hepáticas Dr. Aldo J. Montaño Loza, Dr. Paul Angulo]]></source>
<year>2007</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krawitt]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoimmune hepatitis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1996</year>
<volume>334</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>897-903</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[MG.]]></given-names>
</name>
</person-group>
<source><![CDATA[Autoimmune hepatitis: effect of age on severity of disease and use of new scoring system]]></source>
<year>2008</year>
<publisher-loc><![CDATA[San Francisco, CA ]]></publisher-loc>
<publisher-name><![CDATA[American Association for the Study of Liver Diseases]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeoman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Westbrook]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Chalabi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Portmann]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Heneghan]]></surname>
<given-names><![CDATA[MA.]]></given-names>
</name>
</person-group>
<source><![CDATA[Validation and utility of the new simplified international autoimmune hepatitis group (IAIHG) criteria: an assessment of sensitivity and specificity]]></source>
<year>2008</year>
<publisher-loc><![CDATA[San Francisco, CA ]]></publisher-loc>
<publisher-name><![CDATA[American Association for the Study of Liver Diseases]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muratori]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Granito]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pappas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Muratory]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2009</year>
<volume>49</volume>
<page-range>1782-3</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morillas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Planas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criterios clásicos frente a simplificados en el diagnóstico de la hepatitis autoinmune]]></article-title>
<source><![CDATA[GH CONTINUADA]]></source>
<year>2010</year>
<numero>5</numero>
<issue>5</issue>
<page-range>243-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinoza Herrera]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Correa Arango]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo Gutiérrez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hoyos Duque]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reporte de dos casos de síndrome de sobreposición entre hepatitis autoinmune y cirrosis biliar primaria]]></article-title>
<source><![CDATA[Rev Col Gastroenterol]]></source>
<year>2010</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morillas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bargalló]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatitis autoinmune]]></article-title>
<source><![CDATA[Seminarios de la Fundación Española de Reumatología]]></source>
<year>2018</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>166-73</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orts Costa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zúñiga Cabrera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón Torres]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatitis autoinmune]]></article-title>
<source><![CDATA[An Med Interna]]></source>
<year>2004</year>
<volume>21</volume>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Czaja]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Carpenter]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2004</year>
<volume>40</volume>
<page-range>644-50</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soloway]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Summerskill]]></surname>
<given-names><![CDATA[WHJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baggenstoss]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Geall]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Gitnick]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Elveback]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical, biochemical and histological remission of severe chronic active liver disease a controlled study of treatments and early prognosis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>1972</year>
<volume>63</volume>
<page-range>820-33</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Mulligna]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sherlock]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controlled prospective trial of corticosteroid therapy in active chronic hepatitis]]></article-title>
<source><![CDATA[QJM]]></source>
<year>1971</year>
<volume>40</volume>
<page-range>159-85</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murray-Lyon]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Stern]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controlled trial of prednisone and azathioprine in active chronic hepatitis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1973</year>
<volume>1</volume>
<page-range>735-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Shao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hua]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prog- nostic implications of antibodies to soluble liver antigen in autoimmune hepatitis]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2015</year>
<volume>94</volume>
<numero>23</numero>
<issue>23</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
